Hunter Perkins Capital Management LLC Has $8.40 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Hunter Perkins Capital Management LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% in the 4th quarter, HoldingsChannel reports. The fund owned 10,887 shares of the biopharmaceutical company’s stock after selling 729 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.9% of Hunter Perkins Capital Management LLC’s investment portfolio, making the stock its 13th biggest holding. Hunter Perkins Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $8,403,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $34,000. Finally, Berbice Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity Group lifted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Finally, Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $802.27.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 5,274 shares of company stock valued at $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $737.71 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The firm has a market cap of $77.99 billion, a price-to-earnings ratio of 17.75, a P/E/G ratio of 1.98 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The firm’s 50-day simple moving average is $764.67 and its two-hundred day simple moving average is $707.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the firm earned $12.07 EPS. The company’s revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.